RxDoctor Payments Data

Jason Phillips, MD

Cardiovascular Disease · San Antonio, TXNPI 1558655431

Payments from drug & device makers

$2,428in general payments, 2019–2025

Across 91 payments — averaging $26.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$486
  • Johnson & Johnson$365
  • Impulse Dynamics (USA) Inc.$252
  • Merck$231
  • Cvrx, Inc.$226
  • Lantheus Medical Imaging, Inc.$203
  • plus $665 from 13 others

What the payments were for

  • Food & beverage$2,428100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,428 in reported general payments places this provider in the 35th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$58,857
Medicare patients
447
Services billed
996

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan70$106,736
FarxigaDapagliflozin Propanediol85$103,190
EliquisApixaban72$78,878
XareltoRivaroxaban26$38,172
JardianceEmpagliflozin20$18,853
OzempicSemaglutide18$16,647
MounjaroTirzepatide12$12,707
VascepaIcosapent Ethyl14$8,859
Metoprolol Succinate147$2,627
Atorvastatin Calcium166$1,812
Omega-3 Acid Ethyl Esters12$1,101
Spironolactone85$900
Torsemide16$892
Carvedilol112$784
ClopidogrelClopidogrel Bisulfate52$605

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$164$106,73670 claims
AstraZenecaFarxiga$31$103,19085 claims
PfizerEliquis$14$78,87872 claims
Johnson & JohnsonXarelto$365$38,17226 claims
Boehringer IngelheimJardiance$23$18,85320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →